Proteome Sciences Valuation Multiples

Proteome Sciences is valued at $7M as of September 2026, a 5.3x revenue multiple. In the last fiscal year, Proteome Sciences revenue was $5M and Proteome Sciences EBITDA was ($2M).

Proteome Sciences Overview

About Proteome Sciences

Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.


Founded

1993

HQ

United Kingdom

Employees

32

Financials (Last FY)

Revenue: $5M
EBITDA: ($2M)

EV

$27M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Proteome Sciences Financials

Proteome Sciences reported last fiscal year revenue of $5M and negative EBITDA of ($2M).

In the same fiscal year, Proteome Sciences generated ($108K) in gross profit, ($2M) in EBITDA losses, and had net loss of ($4M).


Proteome Sciences P&L

In the most recent fiscal year, Proteome Sciences reported revenue of $5M and EBITDA of ($2M).

Proteome Sciences is unprofitable as of last fiscal year, with gross margin of (2%), EBITDA margin of (46%), and net margin of (81%).

See analyst estimates for Proteome Sciences
Last FY202320242025202620272028
Revenue$5M$7M$7M$5M
Gross Profit($108K)$2M$897K($108K)
Gross Margin(2%)33%14%(2%)
EBITDA($2M)($2M)($2M)($2M)
EBITDA Margin(46%)(23%)(31%)(46%)
EBIT Margin(71%)(32%)(48%)(71%)
Net Profit($4M)($3M)($5M)($4M)
Net Margin(81%)(49%)(70%)(81%)
Net Debt$19M---

Financial data powered by Morningstar, Inc.

Proteome Sciences Stock Performance

Proteome Sciences has current market cap of $7M, and enterprise value of $27M.


Proteome Sciences' stock price is $0.02.

Proteome Sciences share price decreased by 4.8% in the last 30 days, and by 24.5% in the last year.

Proteome Sciences has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Proteome Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$27M$7M-0.3%-4.8%-10.6%-24.5%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Proteome Sciences Valuation Multiples

Proteome Sciences trades at 5.3x EV/Revenue multiple, and (11.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Proteome Sciences

Proteome Sciences Financial Valuation Multiples

As of September 24, 2026, Proteome Sciences has market cap of $7M and EV of $27M.

Proteome Sciences has a P/E ratio of (1.7x).

Last FY202320242025202620272028
EV/Revenue5.3x4.0x4.1x5.3x
EV/EBITDA(11.5x)(17.6x)(13.2x)(11.5x)
EV/EBIT(7.5x)(12.3x)(8.5x)(7.5x)
EV/Gross Profit(247.4x)12.1x29.8x(247.4x)
P/E(1.7x)(2.1x)(1.5x)(1.7x)
EV/FCF(140.1x)(27.8x)(19.0x)(140.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Proteome Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Proteome Sciences Margins & Growth Rates

In the most recent fiscal year, Proteome Sciences reported gross margin of (2%), EBITDA margin of (46%), and net margin of (81%).

See estimated margins and future growth rates for Proteome Sciences

Proteome Sciences Margins

Last FY20242025202720282029
Gross Margin(2%)14%(2%)
EBITDA Margin(46%)(31%)(46%)
EBIT Margin(71%)(48%)(71%)
Net Margin(81%)(70%)(81%)
FCF Margin(4%)(21%)(4%)

Proteome Sciences Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(3%)(23%)
Gross Profit Growth(59%)(112%)
EBITDA Growth33%14%
EBIT Growth45%13%
Net Profit Growth39%(10%)
FCF Growth46%(86%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Proteome Sciences Operational KPIs

Proteome Sciences' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Proteome Sciences
Last FY202320242025202620272028
Revenue per Employee$0.2M---
Opex per Employee$0.1M---
G&A Expenses to Revenue69%65%62%69%
Opex to Revenue69%65%62%69%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Proteome Sciences Competitors

Proteome Sciences competitors include Co-Diagnostics, IMD Companies, Euroinvestment, Microba Life Sciences, Anatolia Geneworks, Atlantic International, Novacyt, EDX Medical Group, BATM Advanced Communications and hVIVO.

Most Proteome Sciences public comparables operate across Laboratory Services.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Co-Diagnostics$622K($48M)9.3x8.9x(0.1x)-
IMD Companies------
Euroinvestment-($1K)--(2496.5x)-
Microba Life Sciences$11M($8M)2.0x2.0x(2.9x)(3.1x)
Anatolia Geneworks$15M($2M)2.8x-(19.2x)-
Atlantic International$436M($44M)1.4x1.4x(13.6x)-
Novacyt$27M($29M)1.1x1.1x(1.0x)(2.8x)
EDX Medical Group$441K($7M)108.9x-(6.5x)-

This data is available for Pro users. Sign up to see all Proteome Sciences competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Proteome Sciences

When was Proteome Sciences founded?Proteome Sciences was founded in 1993.
Where is Proteome Sciences headquartered?Proteome Sciences is headquartered in United Kingdom.
How many employees does Proteome Sciences have?As of today, Proteome Sciences has over 32 employees.
Is Proteome Sciences publicly listed?Yes, Proteome Sciences is a public company listed on London Stock Exchange.
What is the stock symbol of Proteome Sciences?Proteome Sciences trades under PRM ticker.
When did Proteome Sciences go public?Proteome Sciences went public in 1995.
Who are competitors of Proteome Sciences?Proteome Sciences main competitors include Co-Diagnostics, IMD Companies, Euroinvestment, Microba Life Sciences, Anatolia Geneworks, Atlantic International, Novacyt, EDX Medical Group, BATM Advanced Communications, hVIVO.
What is the current market cap of Proteome Sciences?Proteome Sciences' current market cap is $7M.
What is the current revenue of Proteome Sciences?Proteome Sciences' last fiscal year revenue is $5M.
What is the current EV/Revenue multiple of Proteome Sciences?Current revenue multiple of Proteome Sciences is 5.3x.
Is Proteome Sciences profitable?No, Proteome Sciences is not profitable.
How many companies Proteome Sciences has acquired to date?Proteome Sciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Proteome Sciences has invested to date?Proteome Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Proteome Sciences

Lists including Proteome Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial